지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
오류제보하기
Objective: Nivolumab and pembrolizumab are antagonists of the programmed death-ligand 1 (PD-L1) receptor that function as immuno-oncological agents. This study aimed to evaluate the safety and efficacy of nivolumab and pembrolizumab in elderly patients in outpatient settings. Methods: The safety and efficacy of nivolumab and pembrolizumab were compared retrospectively among patients at the Veterans Health Service (VHS) Medical Center in Seoul, South Korea, from September 1, 2017 to August 25, 2018. Results: Eighty-seven patients were selected for the study. The median progression-free survival was 63 days for nivolumab (95% confidence interval (CI), [14 to 282]) vs. 243 days for pembrolizumab (95% CI, [22 to 348]) (p =0.04). The objective response rate (ORR) was 0% in the nivolumab group vs 5.6% in the pembrolizumab group (p =0.310). All the patients exhibited treatmentrelated adverse effects. More than 89% of the patients exhibited diseases of the gastrointestinal (GI) tract. Pneumonia, of grades three or higher, was the most common adverse effect, followed by weakness and anorexia. Conclusion: There was no statistically significant difference between the nivolumab group and the pembrolizumab group with respect to the ORR. The incidence and severity of the adverse effects in this study were higher than those of previous studies; however, these adverse effects are generally manageable in a real-world clinical setting. Further randomized controlled studies will be necessary to confirm these results in elderly patients.
목차
등록된 정보가 없습니다.
참고문헌 (16)
참고문헌 신청
Siegel RL / 2018 / Cancer statistics, 2018 / Cancer J Clin 68:7~30
정규원 / 2019 / Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2016 / Cancer Research and Treatment 51(2):417~430
Michot JM / 2016 / Immune-related adverse events with immune checkpoint blockade : a comprehensive review / Eur J Cancer 54:139~148
엄고혜 / 2018 / 상급종합병원 암센터에서 Nivolumab 사용평가와 치료성과에 미치는 영향인자 / 한국임상약학회지 28(2):88~94
Kang YK / 2017 / Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to,or intolerant of, at least two previous chemotherapy regimens(ONO-4538-12,ATTRACTION-2): a randomized, double-blind, placebo-controlled, phase 3 trial / Lancet 390:2461~2471
정규원 / 2019 / Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2016 / Cancer Research and Treatment 51(2):417~430
Michot JM / 2016 / Immune-related adverse events with immune checkpoint blockade : a comprehensive review / Eur J Cancer 54:139~148
엄고혜 / 2018 / 상급종합병원 암센터에서 Nivolumab 사용평가와 치료성과에 미치는 영향인자 / 한국임상약학회지 28(2):88~94
Kang YK / 2017 / Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to,or intolerant of, at least two previous chemotherapy regimens(ONO-4538-12,ATTRACTION-2): a randomized, double-blind, placebo-controlled, phase 3 trial / Lancet 390:2461~2471
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Nivolumab, Pembrolizumab의 임상적 사용 적정성, 유효성 및 안전성 평가
병원약사회지
2020 .01
-
PD-1 억제제의 사용패턴 및 갑상선 관련 유해사례 발현 양상 분석
한국임상약학회지
2021 .09
-
Pembrolizumab-Associated Unilateral Optic Neuritis
Journal of Clinical Neurology
2024 .03
-
Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
Clinical and Molecular Hepatology
2020 .01
-
Pembrolizumab for Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma in Korea
Cancer Research and Treatment
2024 .04
-
Real-World Experience with Pembrolizumab Treatment in Patients with Heavily Treated Recurrent Gynecologic Malignancies
Yonsei Medical Journal
2020 .01
-
Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response
Cancer Research and Treatment
2020 .01
-
Primary malignant melanoma of the uterine cervix treated with pembrolizumab after radical surgery: a case report and literature review
Obstetrics & Gynecology Science
2018 .01
-
Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician’s choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer
Journal of Gynecologic Oncology
2024 .03
-
A Case of Nivolumab-Induced Lichen Planus
Annals of Dermatology
2019 .01
-
Real World Experience of Nivolumab in Non-Small Cell Lung Cancer in Korea
Cancer Research and Treatment
2020 .01
-
암환자에서 Pembrolizumab 투여로 인한 혈당수치 변화 분석
한국임상약학회지
2021 .09
-
A Phase I/IIa Randomized Trial Evaluating the Safety and Efficacy of SNK01 Plus Pembrolizumab in Patients with Stage IV Non-Small Cell Lung Cancer
Cancer Research and Treatment
2022 .10
-
Nivolumab-Induced Alopecia Areata: A Case Report and Literature Review
Annals of Dermatology
2021 .01
-
Clinical Efficacy of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer Patients with Liver Metastases: A Network Meta-Analysis of Nine Randomized Controlled Trials
Cancer Research and Treatment
2022 .07
-
Emergence of Myasthenia Gravis with Myositis in a Patient Treated with Pembrolizumab for Thymic Cancer
Journal of Clinical Neurology
2018 .01
-
Pembrolizumab-Induced Myasthenic Crisis with HyperCKemia in a Patient with Thymoma
Journal of Clinical Neurology
2020 .01
-
상급종합병원 암센터에서 Nivolumab 사용평가와 치료성과에 미치는 영향인자
한국임상약학회지
2018 .01
-
Characterization and Prognostic Significance of Cutaneous Adverse Events to Anti-Programmed Cell Death-1 Therapy
Journal of Korean Medical Science
2019 .01
-
Serum PD-1 Levels Change with Immunotherapy Response but Do Not Predict Prognosis in Patients with Hepatocellular Carcinoma
Journal of Liver Cancer
2019 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0